FGFR2 and intrahepatic cholangiocarcinoma: These important contributions comprise the entirety of pre-clinical models of FGFR2 fusion-positive ICC, thus there is a desperate need to develop novel patient-derived models of this disease to optimize the likelihood of translatability in any data generated, and to use these models to discover additional therapeutic strategies with the potential for improved response and durability beyond standard regimens.